Neuronetics Announces That Additional Payors Have Updated Their TMS Coverage To Reduce Access Barriers For Patients With Major Depressive Disorder
Neuronetics Announces That Additional Payors Have Updated Their TMS Coverage To Reduce Access Barriers For Patients With Major Depressive Disorder
Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that additional payors have updated their TMS (transcranial magnetic stimulation) coverage to reduce access barriers for patients with major depressive disorder (MDD). This expanded access allows people to receive treatment such as the Company's NeuroStar TMS Therapy earlier in their treatment regimen.
纳斯达克：适应主要抑郁障碍 (MDD) 病人的神经健康障碍，Neuronetics, Inc. (纳斯达克：STIM)，一家专注于设计、开发和销售改善患者生活质量的医疗技术公司，宣布其他支付人已更新他们的TMS (经颅磁刺激) 覆盖范围，以减少主要抑郁障碍 (MDD) 病人的就医障碍。这种扩大的覆盖范围使人们能够在他们的治疗计划早期接受像公司的NeuroStar TMS疗法这样的治疗。
Effective immediately, BlueCross BlueShield (BCBS) of North Carolina has expanded its TMS policy to cover adolescents 15 years and older, based on recent clearance from the United States Food and Drug Administration (FDA) for NeuroStar as the first and only TMS treatment authorized for this population. BCBC of North Carolina policies affect more than 2.2 million covered lives. Additionally, Louisiana Medicaid has started covering TMS for adults 18 and older, effective immediately. This is the first TMS coverage policy from Louisiana Medicaid, which has a footprint of more than 1.6 million covered lives.
北卡罗来纳州BlueCross BlueShield（BCBS）的TMS政策已立即扩大覆盖范围，针对15岁及以上的青少年，根据美国食品和药物管理局（FDA）对NeuroStar作为首个并且唯一的TMS治疗适用于该人群的最新审批。北卡罗来纳州的BCBC政策影响超过220万的被保人。此外，路易斯安那州医疗补助已经开始覆盖18岁及以上的成年人的TMS治疗，立即生效。这是路易斯安那州医疗补助的首个TMS覆盖政策，影响超过160万的被保人。
